Dashboard
Manage Tickers

RGNX REGENXBIO Inc.

Nasdaq regenxbio.com


$ 12.82 nm (nm)    

Thursday, 30-Oct-2025 17:33:09 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.20 nm (nm)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 nm (nm)
TLT $ 90.42 nm (nm)
GLD $ 371.67 nm (nm)
$ 12.84
$ 12.75
$ 11.75 x 170
$ 13.50 x 4
$ 12.75 - $ 13.26
$ 5.04 - $ 13.93
331,616
na
647.59M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-06-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-07-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-03-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

regenxbio-completes-enrollment-in-affinity-duchenne-pivotal-trial-of-rgx-202-initiates-commercial-production-duchenne-gene-therapy-program
REGENXBIO Completes Enrollment In AFFINITY...
10/30/2025 11:13:50

Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to ...

regenxbio-to-present-data-on-sura-vec-for-diabetic-retinopathy-at-american-academy-of-ophthalmology
REGENXBIO to Present Data on Sura-vec for ...
10/09/2025 11:25:33

REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating sup...

the-analyst-verdict-regenxbio-in-the-eyes-of-7-experts
The Analyst Verdict: Regenxbio In The Eyes...
10/07/2025 20:01:28

7-analysts-assess-regenxbio-what-you-need-to-know
7 Analysts Assess Regenxbio: What You Need...
10/07/2025 13:04:59

hc-wainwright--co-reiterates-buy-on-regenxbio-maintains-34-price-target
HC Wainwright & Co. Reiterates Buy on Rege...
10/07/2025 10:15:49

HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintains $34 price target.

regenxbio-completes-enrollment-in-atmosphere-and-ascent-pivotal-studies-evaluating-surabgene-lomparvovec-in-wet-amd-using-subretinal-delivery
REGENXBIO Completes Enrollment In ATMOSPHE...
10/06/2025 11:10:05

Over 1,200 participants enrolled in ATMOSPHERE® and ASCENT® pivotal trials, representing largest global gene therapy program ev...

regenxbio-to-present-rgx-202-phase-iii-functional-data-at-wms-2025-highlights-nsaa-gains-favorable-safety-profile-vs-natural-history-controls
REGENXBIO To Present RGX-202 Phase I/II Fu...
09/29/2025 11:18:53

REGENXBIO Inc. (NASDAQ: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Cong...

a-glimpse-into-the-expert-outlook-on-regenxbio-through-6-analysts
A Glimpse Into The Expert Outlook On Regen...
09/08/2025 19:01:59

hc-wainwright--co-reiterates-buy-on-regenxbio-maintains-34-price-target
HC Wainwright & Co. Reiterates Buy on Rege...
09/08/2025 11:37:48

HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintains $34 price target.

chardan-capital-maintains-buy-on-regenxbio-maintains-52-price-target
Chardan Capital Maintains Buy on Regenxbio...
09/08/2025 10:59:49

Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.

regenxbio-unveils-12-month-data-for-gene-therapy-soon-after-fda-delays-review-date
Regenxbio Unveils 12-Month Data For Gene T...
09/05/2025 17:51:16

Regenxbio reported sustained biomarker reduction and positive neurodevelopmental outcomes in the pivotal CAMPSIITE trial of RGX...

regenxbio-announces-data-from-phase-iiiiii-campsiite-trial-of-clemidsogene-lanparvovec-for-treatment-of-patients-with-mucopolysaccharidosis-type-ii-at-iciem-2025
REGENXBIO Announces Data From Phase I/II/I...
09/05/2025 11:08:33

12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS I...

fda-extends-decision-date-on-regenxbios-gene-therapy-into-next-year
FDA Extends Decision Date On Regenxbio's G...
08/19/2025 16:01:09

FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new long-t...

analyst-expectations-for-regenxbios-future
Analyst Expectations For Regenxbio's Future
08/19/2025 12:00:44

hc-wainwright--co-reiterates-buy-on-regenxbio-maintains-34-price-target
HC Wainwright & Co. Reiterates Buy on Rege...
08/19/2025 11:00:00

HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintains $34 price target.

regenxbio-reveals-fda-review-extension-of-bla-for-rgx-121-to-treat-patients-with-mps-ii-pdufa-date-extended-to-february-8-2026
REGENXBIO Reveals FDA Review Extension Of ...
08/18/2025 21:04:06

ROCKVILLE, Md., Aug. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that the U.S. Food and Drug Administ...

rbc-capital-maintains-outperform-on-regenxbio-lowers-price-target-to-17
RBC Capital Maintains Outperform on Regenx...
08/08/2025 18:31:58

RBC Capital analyst Luca Issi maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $21 to $17.

barclays-maintains-overweight-on-regenxbio-lowers-price-target-to-37
Barclays Maintains Overweight on Regenxbio...
08/08/2025 14:27:32

Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $50 to $37.

chardan-capital-maintains-buy-on-regenxbio-maintains-52-price-target
Chardan Capital Maintains Buy on Regenxbio...
08/08/2025 12:10:03

Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.

regenxbio-initiates-pivotal-phase-iibiii-suprachoroidal-surabgene-lomparvovec-trial-in-diabetic-retinopathy-following-positive-two-year-altitude-data-abbvie-to-pay-200-million-in-milestones-and-advance-wet-amd-achieve-phase-iii
REGENXBIO Initiates Pivotal Phase IIb/III ...
08/07/2025 11:26:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION